Project Grant K23HL177257
- This federal Project Grant award for $802,301, provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research by Weill Medical College of Cornell University to investigate the mechanisms that control the bone marrow "niche" environment and its role in expanding mutated blood stem cells that increase the risk of cardiovascular disease and cancer. The research aims to identify signaling pathways that can be targeted to prevent...
- This federal Project Grant award of $2,508,095, awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at Yale University to investigate the role of cell-extracellular matrix interactions in the development of thoracic aortic disease. The research aims to elucidate the underlying mechanisms driving thoracic aortopathy, such as aortic aneurysms, dissection, and rupture, in order to identify potential targets for...
- This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $766,667 to the Augusta University Research Institute, Inc. to investigate the role of neddylation, a protein modification process, in the development of cardiovascular diseases. The research aims to determine the significance of neddylation in maintaining vascular smooth muscle cell homeostasis and overall vascular health. Key research activities include...
- This $385,381 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports the development of dynamic biological hydrogels to modulate cardiac remodeling following myocardial infarction. The primary goals are to: 1) Improve the mechanical stability and stiffness of cardiac extracellular matrix hydrogels compared to existing therapies, and 2) Leverage changes in extracellular matrix composition to promote a more regenerative...
- This federal Project Grant award, totaling $753,813 and provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research to develop novel machine learning techniques for predicting cardiovascular outcomes in patients with clonal hematopoiesis of indeterminate potential (CHIP). The key goals are to use cardiac MRI imaging and genomic data to: 1) Develop a machine learning model to accurately identify CHIP patients and predict their risk...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $708,265 in funding to Weill Medical College of Cornell University from September 1, 2025 through June 30, 2029. The research project aims to expand understanding of how fibroblast growth factor homologous factors (FHFs) influence cardiac physiology and how genetic variants contribute to arrhythmias, providing a platform for targeted therapies. Key research objectives...
- This Project Grant award, valued at $733,439.00, was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Michigan. The grant supports research to define the molecular triggers and consequences of CART signaling in aortic smooth muscle cells, and determine the role of sexually dimorphic signaling mechanisms in thoracic aortic aneurysm (TAA) pathogenesis. The research aims to advance the...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $165,672 to New York University School of Medicine to conduct research aimed at increasing heart transplant (HT) volume in the United States. The key objectives are to: Investigate the impact of donor risk factors, such as coronary artery disease, left ventricular dysfunction, and older age, on post-HT outcomes using European and U.S. registry data. This...
- This Project Grant award of $705,405 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The Leland Stanford Junior University supports research focused on characterizing the role of adventitial fibroblasts in atherosclerosis. The research aims to identify new therapeutic targets and pathways related to this understudied cell population's influence on atherosclerotic plaque formation and calcification. The project will leverage single-cell genomics,...
- This $713,382 Project Grant award from the National Heart Lung and Blood Institute's Cardiovascular Diseases Research program (CFDA 93.837) supports research at the University of Pennsylvania on the role of triglyceride-rich lipoproteins in the growth and progression of abdominal aortic aneurysms. The research aims to generate definitive causal evidence on how triglyceride-rich lipoproteins influence the development, growth, and rupture of these life-threatening aortic aneurysms, with the goal...
This federal Project Grant award of $174,389 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research by Dr. Nupoor Narula at Weill Medical College of Cornell University on the impact of aortic grafts on cardiovascular remodeling and outcomes in genetically triggered aortic aneurysms. The 5-year award, beginning September 5, 2025, will leverage advanced cardiac MRI techniques and rigorous genetic analyses to assess how the stiffness of prosthetic aortic grafts, compared to native aortic tissue, affects left ventricular performance and distal aortic remodeling in patients with genetically triggered thoracic aortic aneurysms. The goal is to better understand the mechanisms by which aortic grafts influence adverse cardiovascular changes in this patient population and identify potential genetic factors that may modify the impact of the grafts.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $174.4k | 9/4/25 |